MAPT and Alzheimer disease: The FDA has approved PET-scan imaging with an amyloid-beta and tau probes (Chandra et al., 2019; Afzal et al., 2021; Maschio and Ni, 2022; Wang R. et al., 2023), the most recent ones directed to tau as biomarkers for AD (Xia et al., 2013; Kolb and Andrés, 2017).